TIME-RESTRICTED EATING FOR CHRONIC PLAQUE-TYPE PSORIASIS: A PROSPECTIVE INTERVENTIONAL STUDY ON CLINICAL AND LIFESTYLE OUTCOMES

Abstract

This study evaluated the effectiveness, safety, and patient satisfaction of a 12-week daytime 16:8 Time-Restricted Eating (TRE) regimen on psoriasis severity, anthropometric parameters, sleep quality, and quality of life in overweight and obese adults with chronic plaque-type psoriasis. Results showed statistically significant improvements across all primary outcomes. Following the intervention, mean PASI decreased from 9.21 to 6.00, representing a 34.85% reduction (p < 0.001), with 44.4% of participants achieving a PASI-50 response. Significant weight loss was observed, with mean reductions in body weight (–4.57 kg; 5.63%), BMI (–1.62 kg/m²; 5.61%), and waist circumference (–4.36 cm; 4.65%) (p < 0.001 for all). Lifestyle outcomes improved substantially; sleep quality scores (PSQI) decreased by 29.89%, with 72.2% of participants achieving good sleep quality post-intervention (p < 0.001). Furthermore, quality of life (DLQI) scores improved by 23.26% (p = 0.005), with two-thirds of the cohort reporting enhanced well-being. The intervention was well-tolerated, with only mild, transient side effects and high participant satisfaction (94.4% of willingness to continue). In conclusion, a daytime 16:8 TRE regimen is a safe and effective non-pharmacologic intervention for improving clinical psoriasis severity, metabolic health, sleep, and quality of life. Given the high adherence and positive outcomes, TRE could be a feasible adjunctive lifestyle therapy for managing chronic plaque-type psoriasis in overweight populations.